{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T22:30:18Z","timestamp":1784759418619,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.clml.2017.02.007","type":"journal-article","created":{"date-parts":[[2017,2,16]],"date-time":"2017-02-16T21:32:33Z","timestamp":1487280753000},"page":"207-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients"],"prefix":"10.1016","volume":"17","author":[{"given":"Agustin","family":"Avil\u00e8s","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Jes\u00f9s","family":"Nambo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Huerta-Guzm\u00e0n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Cleto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natividad","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.02.007_bib1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2017.02.007_bib2","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pharmthera.2015.11.008","article-title":"Bisphosphonates for cancer treatment. Mechanisms of action and lessons from clinical trials","volume":"158","author":"VanAcker","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clml.2017.02.007_bib3","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC myeloma IX trial. Survival outcomes with bisphosphonates and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2017.02.007_bib4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer. Consensus evidence for clinical practice from a European panel","volume":"27","author":"Powles","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.02.007_bib5","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02698044","article-title":"Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma","volume":"24","author":"Aviles","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/j.clml.2017.02.007_bib6","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.3747\/co.20.1055","article-title":"Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplant","volume":"20","author":"Avil\u00e9s","year":"2013","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2017.02.007_bib7","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International Myeloma Working Group: recommendation for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.007_bib8","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1182\/blood-2011-11-392522","article-title":"Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.02.007_bib9","first-page":"30","article-title":"A\u00a0retrospective study of skeletal and disease-free survival benefit of zoledronic acid therapy in patients with multiple myeloma treated with novel agents","volume":"7","author":"Ria","year":"2013","journal-title":"Int J Clin Exp Med"},{"key":"10.1016\/j.clml.2017.02.007_bib10","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1185\/03007995.2012.689254","article-title":"Evaluation of the clinical benefit of long-term (beyond > 2 years) treatment of skeletal related events in advanced cancer with zoledronic acid","volume":"28","author":"Henk","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2017.02.007_bib11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3324\/haematol.2015.128439","article-title":"Zoledronic acid as compared with observation in multiple myeloma patients at biochemical disease. Results of the randomized AZABACHE Spanish trial","volume":"100","author":"Garcia-Sanz","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.02.007_bib12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1038\/leu.2012.236","article-title":"A\u00a0phase II randomized clinical trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma","volume":"27","author":"Witzing","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2017.02.007_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3109\/10428194.2014.924117","article-title":"Comparing effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma","volume":"56","author":"SanFilippo","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.02.007_bib14","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00432-014-1853-6","article-title":"Risk factors influence the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw 913 cancer patients","volume":"141","author":"Garbert","year":"2015","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clml.2017.02.007_bib15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A\u00a0systematic review of persistence and compliance with bisphosphonates and osteoporosis","volume":"18","author":"Cramel","year":"2007","journal-title":"Osteoporos Int"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016306267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265016306267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:27:55Z","timestamp":1761870475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265016306267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["S2152265016306267"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.007","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}